These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14641514)

  • 41. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
    J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.
    Sruamsiri R; Dilokthornsakul P; Pratoomsoot C; Chaiyakunapruk N
    Pharmacoeconomics; 2014 Aug; 32(8):801-13. PubMed ID: 24849397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.
    Finch AP; van Velzen P; Ter Riet G; Sterk PJ; Prins JM; Bosmans JE
    Pharmacoeconomics; 2019 May; 37(5):689-699. PubMed ID: 30565022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.
    RMC Trial Group
    Lancet Neurol; 2009 Feb; 8(2):158-64. PubMed ID: 19136303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interspinous process devices versus standard conventional surgical decompression for lumbar spinal stenosis: cost-utility analysis.
    van den Akker-van Marle ME; Moojen WA; Arts MP; Vleggeert-Lankamp CL; Peul WC;
    Spine J; 2016 Jun; 16(6):702-10. PubMed ID: 25452018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
    Adrichem ME; Eftimov F; van Schaik IN
    J Peripher Nerv Syst; 2016 Sep; 21(3):121-7. PubMed ID: 27241239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
    Iijima M; Koike H; Sobue G
    Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.
    Hartman L; El Alili M; Cutolo M; Opris D; Da Silva J; Szekanecz Z; Buttgereit F; Masaryk P; Bos R; Kok MR; Paolino S; Coupé V; Lems WF; Boers M;
    Semin Arthritis Rheum; 2022 Dec; 57():152109. PubMed ID: 36335684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current treatments for CIDP.
    Ropper AH
    Neurology; 2003 Apr; 60(8 Suppl 3):S16-22. PubMed ID: 12707418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
    Cornblath DR; van Doorn PA; Hartung HP; Merkies ISJ; Katzberg HD; Hinterberger D; Clodi E;
    Brain; 2022 Apr; 145(3):887-896. PubMed ID: 35038723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic evaluation of an extended nutritional intervention in older Australian hospitalized patients: a randomized controlled trial.
    Sharma Y; Thompson C; Miller M; Shahi R; Hakendorf P; Horwood C; Kaambwa B
    BMC Geriatr; 2018 Feb; 18(1):41. PubMed ID: 29402228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study.
    Merkies IS; Hughes RA; Donofrio P; Bril V; Dalakas MC; Hanna K; Hartung HP; Latov N; van Doorn PA; Deng C;
    J Peripher Nerv Syst; 2010 Sep; 15(3):208-15. PubMed ID: 21040143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prednicarbate versus fluocortin for inflammatory dermatoses. A cost-effectiveness study.
    de Tiedra A; Mercadal J; Lozano R
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 1):193-208. PubMed ID: 10169671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Utility and Cost-Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis.
    Cuperus N; van den Hout WB; Hoogeboom TJ; van den Hoogen FH; Vliet Vlieland TP; van den Ende CH
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):502-10. PubMed ID: 26314289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
    Hahn AF; Bolton CF; Zochodne D; Feasby TE
    Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.